News

October 21, 2025

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

August 27, 2025

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

August 20, 2025

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

August 5, 2025

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

July 22, 2025

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

July 12, 2025

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

July 10, 2025

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

July 9, 2025

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

July 9, 2025

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

July 8, 2025

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity